PHP
WGS icon

Parkman Healthcare Partners’s GeneDx Holdings WGS Stock Holding History

Parkman Healthcare Partners’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,778
Closed -$3.26M – 106
2026
Q1 		$3.26M Buy
50,778
+11,506
+29% +$1.05M 0.34% 73
2025
Q4 		$5.11M Sell
39,272
-5,978
-13% -$821K 0.49% 62
2025
Q3 		$4.88M Sell
45,250
-129,750
-74% -$14.1M 0.51% 64
2025
Q2 		$16.2M Buy
+175,000
New +$13.7M 1.86% 18

Other funds holding WGS

Corvex Management
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Parkman Healthcare Partners's WGS Position: Q2 2026 in Review

Parkman Healthcare Partners sold out of GeneDx Holdings (WGS) in Q2 2026, closing a stake of 50,778 shares — an estimated $3.26M sold.

Parkman Healthcare Partners first reported a position in WGS in Q2 2025 and held it in 4 quarters. The position peaked at $16.2M in Q2 2025. 223 funds tracked by Wall St. Rank hold WGS as of Q2 2026.

  • Parkman Healthcare Partners reported no remaining GeneDx Holdings position as of Q2 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 50,778 GeneDx Holdings shares in Q2 2026, an estimated $3.26M.
  • Parkman Healthcare Partners first reported a position in GeneDx Holdings in Q2 2025 and held it in 4 quarters.
  • Parkman Healthcare Partners's GeneDx Holdings position peaked at $16.2M in Q2 2025.
  • 223 funds tracked by Wall St. Rank held GeneDx Holdings as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.